Monopar Therapeutics Inc.

NasdaqCM:MNPR Stock Report

Market Cap: US$287.3m

Monopar Therapeutics Valuation

Is MNPR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MNPR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$166.11
Fair Value
70.8% undervalued intrinsic discount
4
Number of Analysts

Below Fair Value: MNPR ($48.46) is trading below our estimate of fair value ($166.11)

Significantly Below Fair Value: MNPR is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MNPR?

Key metric: As MNPR is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for MNPR. This is calculated by dividing MNPR's market cap by their current book value.
What is MNPR's PB Ratio?
PB Ratio59.7x
BookUS$4.95m
Market CapUS$287.30m

Price to Book Ratio vs Peers

How does MNPR's PB Ratio compare to its peers?

The above table shows the PB ratio for MNPR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average2.1x
FDMT 4D Molecular Therapeutics
0.5x-3.3%US$301.4m
CCCC C4 Therapeutics
1x30.4%US$252.7m
CATX Perspective Therapeutics
0.7x2.2%US$230.5m
SGMO Sangamo Therapeutics
6.1x49.4%US$265.0m
MNPR Monopar Therapeutics
59.7x28.4%US$287.3m

Price-To-Book vs Peers: MNPR is expensive based on its Price-To-Book Ratio (59.7x) compared to the peer average (2.1x).

Price to Book Ratio vs Industry

How does MNPR's PB Ratio compare vs other companies in the US Biotechs Industry?

72 CompaniesPrice / BookEstimated GrowthMarket Cap
SLRN Acelyrin
0.4x16.8%US$190.62m
LYEL Lyell Immunopharma
0.3x-13.7%US$172.67m
NKTX Nkarta
0.4x-8.3%US$165.13m
FATE Fate Therapeutics
0.4x-4.1%US$159.45m
MNPR 59.7xIndustry Avg. 1.6xNo. of Companies78PB01.63.24.86.48+
72 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: MNPR is expensive based on its Price-To-Book Ratio (59.7x) compared to the US Biotechs industry average (1.7x).

Price to Book Ratio vs Fair Ratio

What is MNPR's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MNPR PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio59.7x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate MNPR's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst MNPR forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$48.46
US$52.25
+7.8%
27.6%US$72.00US$37.00n/a4
Feb ’26US$43.94
US$46.50
+5.8%
31.8%US$72.00US$37.00n/a4
Jan ’26US$22.00
US$27.33
+24.2%
25.1%US$37.00US$22.00n/a3
Dec ’25US$22.53
US$27.33
+21.3%
25.1%US$37.00US$22.00n/a3
Nov ’25US$14.63
US$18.07
+23.5%
49.4%US$30.20US$9.00n/a3
Oct ’25US$5.08
US$18.07
+255.6%
49.4%US$30.20US$9.00n/a3
Sep ’25US$2.39
US$18.07
+655.9%
49.4%US$30.20US$9.00n/a3
Aug ’25US$3.47
US$11.93
+244.3%
18.4%US$15.00US$10.00n/a3
Jul ’25US$3.71
US$10.40
+180.6%
3.8%US$10.80US$10.00n/a2
Jun ’25US$3.06
US$10.40
+240.4%
3.8%US$10.80US$10.00n/a2
May ’25US$3.25
US$16.82
+417.4%
55.4%US$30.00US$10.00n/a3
Apr ’25US$3.40
US$20.23
+495.7%
48.3%US$30.00US$10.45n/a2
Mar ’25US$4.48
US$42.73
+853.8%
75.5%US$75.00US$10.45n/a2
Feb ’25US$1.85
US$42.73
+2,205.1%
75.5%US$75.00US$10.45US$43.942
Jan ’25US$1.70
US$42.73
+2,411.8%
75.5%US$75.00US$10.45US$22.002
Dec ’24US$1.65
US$42.73
+2,489.4%
75.5%US$75.00US$10.45US$22.532
Nov ’24US$2.75
US$42.50
+1,445.5%
76.5%US$75.00US$10.00US$14.632
Oct ’24US$3.10
US$42.50
+1,271.2%
76.5%US$75.00US$10.00US$5.082
Sep ’24US$3.19
US$42.50
+1,234.4%
76.5%US$75.00US$10.00US$2.392
Aug ’24US$3.63
US$46.25
+1,175.9%
73.5%US$85.00US$10.00US$3.474
Jul ’24US$4.28
US$46.25
+981.9%
73.5%US$85.00US$10.00US$3.714
Jun ’24US$5.25
US$46.25
+781.0%
73.5%US$85.00US$10.00US$3.064
May ’24US$5.20
US$51.25
+885.6%
57.5%US$85.00US$15.00US$3.254
Apr ’24US$6.95
US$51.25
+637.4%
57.5%US$85.00US$15.00US$3.404
Mar ’24US$13.95
US$96.00
+588.2%
64.1%US$200.00US$30.00US$4.485
Feb ’24US$15.80
US$96.45
+510.4%
63.3%US$200.00US$32.25US$1.855
Analyst Price Target
Consensus Narrative from 4 Analysts
US$52.25
Fair Value
7.3% undervalued intrinsic discount
4
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 01:24
End of Day Share Price 2025/02/07 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Monopar Therapeutics Inc. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kumaraguru RajaBrookline Capital Markets
Brian Kemp DolliverBrookline Capital Markets
Sean LeeH.C. Wainwright & Co.